Radioprotective agents for the prevention of side effects induced by radioiodine-131 therapy

Future Oncology

Volumn 9, Issue 8, 2013, Pages 1145-1159

  Noaparast, Zohreh ^a   Hosseinimehr, Seyed Jalal ^a  

^a MAZANDARAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

131I; radioiodine; radioprotective; salivary gland; thyroid

Indexed keywords

ALPHA TOCOPHEROL; AMIFOSTINE; ANTIBIOTIC AGENT; CATALASE; CURCUMA LONGA EXTRACT; GINKGO BILOBA EXTRACT; GLUTATHIONE; GLUTATHIONE TRANSFERASE; IODINE 131; MALONALDEHYDE; MOUTHWASH; OCIMUM SANCTUM EXTRACT; PILOCARPINE; RADIOPROTECTIVE AGENT; REACTIVE OXYGEN METABOLITE; SUPEROXIDE DISMUTASE; ZINC;

ANTIOXIDANT ACTIVITY; CANDIDIASIS; CHILL; CURCUMA LONGA; DETOXIFICATION; DNA PACKAGING; DNA STRAND BREAKAGE; DRUG HALF LIFE; DRUG MEGADOSE; DYSPHAGIA; FIBROSING ALVEOLITIS; FLUID RETENTION; FLUSHING; GASTRITIS; HUMAN; HYPOCALCEMIA; HYPOTENSION; IN VITRO STUDY; IN VIVO STUDY; IONIZING RADIATION; KIDNEY INJURY; LEMON JUICE; LIPID PEROXIDATION; MALAISE; OCIMUM TENUIFLORUM; OXIDATIVE STRESS; PAROTID GLAND DISEASE; PLANT LEAF; PRIORITY JOURNAL; QUALITY OF LIFE; RADIATION EXPOSURE; RADIATION INJURY; RADIATION PROTECTION; REVIEW; SALIVARY GLAND DISEASE; SIALOADENITIS; SIDE EFFECT; SNEEZING; SOMNOLENCE; STOMATITIS; THRUSH; VOMITING; XEROSTOMIA;

CHEWING GUM; CITRUS; GRAVES DISEASE; HUMANS; IODINE RADIOISOTOPES; PLANT EXTRACTS; RADIATION-PROTECTIVE AGENTS; RADIOTHERAPY; SALIVARY GLANDS;

EID: 84881268593     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.13.79     Document Type: Review

References (217)

1. Brizel DM. Pharmacologic approaches to radiation protection. J. Clin. Oncol. 25 (26), 4084-4089 (2007).
2. Mell LK, Movsas B. Pharmacologic normal tissue protection in clinical radiation oncology: Focus on amifostine. Expert Opin. Drug Metab. Toxicol. 4 (10), 1341-1350 (2008).
3. Narra VR, Howell RW, Sastry KS, Rao DV. Vitamin C as a radioprotector against iodine-131 in vivo. J. Nucl. Med. 34 (4), 637-640 (1993).
4. Bohuslavizki KH, Klutmann S, Jenicke L et al. Radioprotection of salivary glands by S-2- (3-aminopropylamino)-ethylphosphorothioic (amifostine) obtained in a rabbit animal model. Int. J. Radiat. Oncol. Biol. Phys. 45 (1), 181-186 (1999).
5. Bohuslavizki KH, Brenner W, Lassmann S et al. Quantitative salivary gland scintigraphy - a recommended examination prior to and after radioiodine therapy. Nuklearmedizin 36 (3), 103-109 (1997).
6. Chow SM. Side effects of high-dose radioactive iodine for ablation or treatment of differentiated thyroid carcinoma. J. HK Coll. Radiol. 8, 127-135 (2005).
7. Nostrand DV, Neutze J, Atkins F. Side effects of 'rational dose' iodine-131 therapy for metastatic well-differentiated thyroid carcinoma. J. Nucl. Med. 27, 1519-1527 (1986).
8. Samuel AM, Unnikrishnan TP, Baghel NS, Rajashekharrao B. Effect of radioiodine therapy on pulmonary alveolar-capillary membrane integrity. J. Nucl. Med. 36 (5), 783-787 (1995).
9. Walter MA, Turtschi CP, Schindler C, Minnig P, Muller-Brand J, Muller B. The dental safety profile of high-dose radioiodine therapy for thyroid cancer: Long-term results of a longitudinal cohort study. J. Nucl. Med. 48 (10), 1620-1625 (2007).
10. Bhartiya US, Raut YS, Joseph LJ, Hawaldar RW, Rao BS. Evaluation of the radio protective effect of turmeric extract and vitamin E in mice exposed to therapeutic dose of radioiodine. Ind. J. Clin. Biochem. 23 (4), 382-386 (2008).
11. Grewal RK, Larson SM, Pentlow CE et al. Salivary gland side effects commonly develop several weeks after initial radioactive iodine ablation. J. Nucl. Med. 50 (10), 1605-1610 (2009).
12. Hyer S, Kong A, Pratt B, Harmer C. Salivary gland toxicity after radioiodine therapy for thyroid cancer. Clin. Oncol. 19 (1), 83-86 (2007).
13. Ish-Shalom S, Durleshter L, Segal E, Nagler RM. Sialochemical and oxidative analyses in radioactive I131-treated patients with thyroid carcinoma. Eur. J. Endocrinol. 158 (5), 677-681 (2008).
14. Kita T, Yokoyama K, Higuchi T et al. Multifactorial analysis on the short-term side effects occurring within 96 hours after radioiodine-131 therapy for differentiated thyroid carcinoma. Ann. Nucl. Med. 18 (4), 345-349 (2004).
15. Silberstein EB. Reducing the incidence of 131I-induced sialadenitis: The role of pilocarpine. J. Nucl. Med. 49 (4), 546-549 (2008).
16. Alexander C, Bader JB, Schaefer A, Finke C, Kirsch CM. Intermediate and long-term side effects of high-dose radioiodine therapy for thyroid carcinoma. J. Nucl. Med. 39 (9), 1551-1554 (1998).
17. Delaviejo A, Dohan O, Levy O, Carrasco N. Molecular analysis of the sodium/iodide symporter: Impact on thyroid and extrathyroid pathophysiology. Am. Physiol. Soc. 80 (3), 1083-1105 (2000).
18. Dougles Van N, Janet N, Franco A. Side effects of "rational dose" iodine-131 therapy for metastatic well differentiated thyroid carcinoma. J. Nucl. Med. 27, 1519 (1986).
19. Newkirk KA, Ringel MD, Wartofsky L, Burman KD. The role of radioactive iodine in salivary gland dysfunction. Ear Nose Throat J. 79 (6), 460-468 (2000).
20. Shen DH, Kloos RT, Mazzaferri EL, Jhian SM. Sodium iodide symporter in health and disease. Thyroid 11 (5), 415-425 (2001).
21. Shen DHY, Cheng CY, Jhiang SM, Huang WS. Sodium iodide symporter (Na+/I-symporter) in radionuclide imaging and radionuclide therapy. Nucl. Med. Sci. 16 (2), 85-96 (2003).
22. Solans R, Bosch JA, Galofre P et al. Salivary and lacrimal gland dysfunction (Sicca syndrome) after radioiodine therapy. J. Nucl. Med. 42 (5), 738-743 (2001).
23. Albrecht HH, Creutzig H. [Salivary gland scintigraphy after radio-iodine therapy. Functional scintigraphy of the salivary gland after high dose radio-iodine therapy (author's transl)]. Rofo 125 (6), 546-551 (1976).
24. Konings AW, Coppes RP, Vissink A. On the mechanism of salivary gland radiosensitivity. Int. J. Radiat. Oncol. Biol. Phys. 62 (4), 1187-1194 (2005).
25. Klubo-Gwiezdzinska J, Van Nostrand D, Burman KD et al. Salivary gland malignancy and radioiodine therapy for thyroid cancer. Thyroid 20 (6), 647-651 (2010).
26. Raymond JP, Izembart M, Marliac V et al. Temporary ovarian failure in thyroid cancer patients after thyroid remnant ablation with radioactive iodine. J. Clin. Endocrinol. Metab. 69 (1), 186-190 (1989).
27. Vini L, Hyer S, Al-Saadi A, Pratt B, Harmer C. Prognosis for fertility and ovarian function after treatment with radioiodine for thyroid cancer. Postgrad. Med. J. 78 (916), 92-93 (2002).
28. Kloos RT. Protecting thyroid cancer patients from untoward effects of radioactive iodine treatment. Thyroid 19 (9), 925-928 (2009).
29. Arora R, Gupta D, Chawla R et al. Radioprotection by plant products: Present status and future prospects. Phytother. Res 19 (1), 1-22 (2005).
30. Halliwell B. Antioxidants in human health and disease. Annu. Rev. Nutr. 16, 33-50 (1996).
31. Nair CK, Parida DK, Nomura T. Radioprotectors in radiotherapy. J. Radiat. Res. 42 (1), 21-37 (2001).
32. Levy O, De La Vieja A, Carrasco N. The Na+/I- symporter (NIS): Recent advances. J. Bioenerg. Biomembr. 30 (2), 195-206 (1998).
33. Spitzweg C, Heufelder AE. The sodium iodide symporter: Its emerging relevance to clinical thyroidology. Eur. J. Endocrinol. 138 (4), 374-375 (1998).
34. Smanik PA, Liu Q, Furminger TL et al. Cloning of the human sodium lodide symporter. Biochem. Biophys. Res. Commun. 226 (2), 339-345 (1996).
35. Chung JK. Sodium iodide symporter: Its role in nuclear medicine. J. Nucl. Med. 43 (9), 1188-1200 (2002).
36. Spitzweg C, Joba W, Schriever K, Goellner JR, Morris JC, Heufelder AE. Analysis of human sodium iodide symporter immunoreactivity in human exocrine glands. J. Clin. Endocrinol. Metab. 84 (11), 4178-4184 (1999).
37. Zeraatpishe A, Oryan S, Bagheri MH et al. Effects of Melissa officinalis L. on oxidative status and DNA damage in subjects exposed to long-term low-dose ionizing radiation. Toxicol. Ind. Health 27 (3), 205-212 (2011).
38. Baum BJ. Principles of saliva secretion. Ann. N.Y. Acad. Sci. 694, 17-23 (1993).
39. Helman J, Turner RJ, Fox PC, Baum BJ. 99mTc-pertechnetate uptake in parotid acinar cells by the Na+/K+/Cl- co-transport system. J. Clin. Invest. 79 (5), 1310-1313 (1987).
40. Kutta H, Kampen U, Sagowski C, Brenner W, Bohuslavizki KH, Paulsen F. Amifostine is a potent radioprotector of salivary glands in radioiodine therapy. Structural and ultrastructural findings. Strahlenther. Onkol. 181 (4), 237-245 (2005).
41. Hoelzer S, Steiner D, Bauer R et al. Current practice of radioiodine treatment in the management of differentiated thyroid cancer in Germany. Eur J. Nucl. Med. 27 (10), 1465-1472 (2000).
42. Kielbassa AM, Hinkelbein W, Hellwig E, Meyer-Luckel H. Radiation-related damage to dentition. Lancet Oncol. 7 (4), 326-335 (2006).
43. Malpani B, Samuel A, Ray S. Quantification of salivary gland function in thyroid cancer patients treated with radioiodine. Int. J. Radiat. Oncol. Biol. Phys. 35 (3), 535-540 (1996).
44. Mandel SJ, Mandel L. Radioactive iodine and the salivary glands. Thyroid 13 (3), 265-271 (2003).
45. Markitziu A, Lustmann J, Uzieli B, Krausz Y, Chisin R. Salivary and lacrimal gland involvement in a patient who had undergone a thyroidectomy and was treated with radioiodine for thyroid cancer. Oral Surg. Oral Med. Oral Pathol. 75 (3), 318-322 (1993).
46. Stone HB, Coleman CN, Anscher MS, Mcbride WH. Effects of radiation on normal tissue: Consequences and mechanisms. Lancet Oncol. 4 (9), 529-536 (2003).
47. Allweiss P, Braunstein GD, Katz A, Waxman A. Sialadenitis following I-131 therapy for thyroid carcinoma: Concise communication. J. Nucl. Med. 25 (7), 755-758 (1984).
48. Levenson D, Gulec S, Sonenberg M, Lai E, Goldsmith SJ, Larson SM. Peripheral facial nerve palsy after high-dose radioiodine therapy in patients with papillary thyroid carcinoma. Ann. Intern. Med. 120 (7), 576-578 (1994).
49. Maier H, Bihl H. Effect of radioactive iodine therapy on parotid gland function. Acta Otolaryngol. 103 (3-4), 318-324 (1987).
50. Ship JA, Mccutcheon JA, Spivakovsky S, Kerr AR. Safety and effectiveness of topical dry mouth products containing olive oil, betaine, and xylitol in reducing xerostomia for polypharmacy-induced dry mouth. J. Oral Rehabil. 34 (10), 724-732 (2007).
51. Dardano A, Ballardin M, Ferdeghini M et al. Anticlastogenic effect of Ginkgo biloba extract in Graves' disease patients receiving radioiodine therapy. J. Clin. Endocrinol. Metab. 92 (11), 4286-4289 (2007).
52. Hernandez-Jardines A, Molina B, Del Castillo V et al. Detection of short-term chromosomal damage due to therapeutic 131I exposure in patients with thyroid cancer. Rev. Invest. Clin. 62 (1), 31-38 (2010).
53. Iarmarcovai G, Ceppi M, Botta A, Orsiere T, Bonassi S. Micronuclei frequency in peripheral blood lymphocytes of cancer patients: A meta-analysis. Mutat. Res. 659 (3), 274-283 (2008).
54. Khouw AS, Parthasarathy S, Witztum JL. Radioiodination of low density lipoprotein initiates lipid peroxidation: Protection by use of antioxidants. J. Lipid Res. 34 (9), 1483-1496 (1993).
55. Hosseinimehr SJ. Potential utility of radioprotective agents in the practice of nuclear medicine. Cancer Biother. Radiopharm. 24 (6), 723-731 (2009).
56. Szumiel I. Radiation hormesis: Autophagy and other cellular mechanisms. Int. J. Radiat. Biol. 88 (9), 619-628 (2012).
57. Fajardo LF. The pathology of ionizing radiation as defined by morphologic patterns. Acta Oncol. 44 (1), 13-22 (2005).
58. Grundmann O, Mitchell GC, Limesand KH. Sensitivity of salivary glands to radiation: From animal models to therapies. J. Dent. Res. 88 (10), 894-903 (2009).
59. Radfar L, Sirois DA. Structural and functional injury in minipig salivary glands following fractionated exposure to 70 Gy of ionizing radiation: An animal model for human radiation-induced salivary gland injury. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 96 (3), 267-274 (2003).
60. Uma Devi P. Radioprotective, anticarcinogenic and antioxidant properties of the Indian holy basil, Ocimum sanctum (Tulasi). Ind. J. Exp. Biol. 39 (3), 185-190 (2001).
61. Davies KJ. Oxidative stress, antioxidant defenses, and damage removal, repair, and replacement systems. IUBMB Life 50 (4-5), 279-289 (2000).
62. Grunwald F, Schomburg A, Menzel C et al. Changes in the blood picture after radioiodine therapy of thyroid cancer. Med. Klin. (Munich) 89 (10), 522-528 (1994).
63. Kasuba V. Biological effects of the iodine 131 radionuclide. Arh. Hig. Rada. Toksikol. 48 (2), 247-257 (1997).
64. Wolfram RM, Budinsky AC, Palumbo B, Palumbo R, Sinzinger H. Radioiodine therapy induces dose-dependent in vivo oxidation injury: Evidence by increased isoprostane 8-epi-PGF (2a). J. Nucl. Med. 43 (9), 1254-1258 (2002).
65. Dani V, Dhawan D. Zinc as an antiperoxidative agent following iodine-131 induced changes on the antioxidant system and on the morphology of red blood cells in rats. Hell J. Nucl. Med. 9 (1), 22-26 (2006).
66. Edwards JC, Chapman D, Cramp WA, Yatvin MB. The effects of ionizing radiation on biomembrane structure and function. Prog. Biophys. Mol. Biol. 43 (1), 71-93 (1984).
67. Bessis M. Red cell shapes. An illustrated classification and its rationale. Nouv. Rev. Fr. Hematol. 12 (6), 721-745 (1972).
68. Tkeshelashvili LK, Tsakadze KJ, Khulusauri OV. Effect of some nickel compounds on red blood cell characteristics. Biol. Trace Elem. Res. 21, 337-342 (1989).
69. Blomfield GW, Eckert H, Fisher M, Miller H, Munro DS, Wilson GM. Treatment of thyrotoxicosis with 131I; a review of 500 cases. Br. Med. J. 1 (5114), 63-74 (1959).
70. Konukoglu D, Hatemi HH, Arikan S, Demir M, Akcay T. Radioiodine treatment and oxidative stress in thyroidectomised patients for differentiated thyroid cancers. Pharmacol. Res. 38 (4), 311-315 (1998).
71. Palecz D, Leyko W. Effect of g radiation on enzymatic activity and sulphydryl groups of human erythrocyte membrane. Int. J. Radiat. Biol. Relat. Stud. Phys. Chem. Med. 44 (3), 293-299 (1983).
72. Bartoc R, Dumitrescu C, Belgun M, Olinescu R. Oxidative and antioxidative factors in the serum of thyroid cancer patients treated with 131I. Rom. J. Endocrinol. 31 (1-2), 85-87 (1993).
73. Makarewicz J, Lewinski A, Karbownik-Lewinska M. Radioiodine remnant ablation of differentiated thyroid cancer does not further increase oxidative damage to membrane lipids - early effect. Thyroid. Res. 3 (1), 7 (2010).
74. Sies H. Biochemistry of oxidant stress. Angew. Chem. Int. Ed. Engl. 25 (12), 1058-1071 (1986).
75. Yildiz M, Cicek E, Gumus BA et al. Oxidative stress of radioiodine treatment in patients with hyperthyroidism. Turk. J. Med. Sci. 38 (5), 405-408 (2008).
76. Jaffiol C, Daures JP, Nsakala N et al. Long term follow up of medical treatment of differentiated thyroid cancer. Ann. Endocrinol. (Paris) 56 (2), 119-126 (1995).
77. Ballardin M, Gemignani F, Bodei L et al. Formation of micronuclei and of clastogenic factor (s) in patients receiving therapeutic doses of iodine-131. Mutat. Res. 514 (1-2), 77-85 (2002).
78. Gutierrez S, Carbonell E, Galofre P, Creus A, Marcos R. Cytogenetic damage after 131-iodine treatment for hyperthyroidism and thyroid cancer. A study using the micronucleus test. Eur J. Nucl. Med. 26 (12), 1589-1596 (1999).
79. Watanabe N, Kanegane H, Kinuya S et al. The radiotoxicity of 131I therapy of thyroid cancer: Assessment by micronucleus assay of B lymphocytes. J. Nucl. Med. 45 (4), 608-611 (2004).
80. Grudeva-Popova J, Yaneva M, Zisov K, Ananoshtev N. Therapy-related acute promyelocytic leukemia after treatment with radioiodine for thyroid cancer: Case report with literature review. J. BUON 12 (1), 129-132 (2007).
81. Schroeder T, Kuendgen A, Kayser S et al. Therapy-related myeloid neoplasms following treatment with radioiodine. Haematologica 97 (2), 206-212 (2012).
82. Kolade VO, Bosinski TJ, Ruffy EL. Acute promyelocytic leukemia after iodine-131 therapy for Graves' disease. Pharmacotherapy 25 (7), 1017-1020 (2005).
83. Edmonds CJ, Smith T. The long-term hazards of the treatment of thyroid cancer with radioiodine. Br. J. Radiol. 59 (697), 45-51 (1986).
84. De Vathaire F, Schlumberger M, Delisle MJ et al. Leukaemias and cancers following iodine-131 administration for thyroid cancer. Br. J. Cancer 75 (5), 734-739 (1997).
85. Beilsk BH. Chemistry of ascorbic acid chemistry metabolism and uses. Adv. Chem. Ser. 200, 81-100 (1982).
86. Hemila H, Roberts P, Wikstrom M Activated polymorphonuclear leucocytes consume vitamin C. FEBS Lett. 178 (1), 25-30 (1984).
87. Littarru GP, Lippa S, De Sole P, Oradei A, Dalla Torre F, Macri M. Quenching of singlet oxygen by d-a-tocopherol in human granulocytes. Biochem. Biophys. Res. Commun. 119 (3), 1056-1061 (1984).
88. Priyadarsini KI. Molecular mechanisms involving free radical reactions of antioxidants and radioprotectors. Barc. Newslett. (261), 1-6 (2005).
89. Gutteridge JM. Lipid peroxidation and antioxidants as biomarkers of tissue damage. Clin. Chem. 41 (12 Pt 2), 1819-1828 (1995).
90. Whitney E, Rolfes SR. Understanding Nutrition (12th Edition). Wadsworth, Cengage Learning, CA, USA (2011).
91. Singh VK, Brown DS, Kao TC. a-tocopherol succinate protects mice from g-radiation by induction of granulocyte-colony stimulating factor. Int. J. Radiat. Biol. 86 (1), 12-21 (2010).
92. Erin AN, Spirin MM, Tabidze LV, Kagan VE. Formation of a-tocopherol complexes with fatty acids. A hypothetical mechanism of stabilization of biomembranes by vitamin E. Biochim. Biophys. Acta 774 (1), 96-102 (1984).
93. Pascoe GA, Fariss MW, Olafsdottir K, Reed DJ. A role of vitamin E in protection against cell injury. Maintenance of intracellular glutathione precursors and biosynthesis. Eur. J. Biochem. 166 (1), 241-247 (1987).
94. Sert C, Çelik MS, Akdag Z, Ketani MA, Nergiz Y. The radioprotective effect of vitamins C, E and vitamin E + glutathione on the small intestine and the thyroid gland in rats irradiated with x-rays. Turk. J. Med. Sci. 30, 417-425 (2000).
95. Shabon MH. Use of curcuma as a radioprotector. Proc. 3rd Environ. Physics Conf. 167-173 (2008).
96. Akpolat M, Kanter M, Uzal MC. Protective effects of curcumin against g radiation-induced ileal mucosal damage. Arch. Toxicol. 83 (6), 609-617 (2009).
97. Cohly HH, Taylor A, Angel MF, Salahudeen AK. Effect of turmeric, turmerin and curcumin on H2O2-induced renal epithelial (LLC-PK1) cell injury. Free Radic. Biol. Med. 24 (1), 49-54 (1998).
98. Subramanian M, Sreejayan Rao MN, Devasagayam TP, Singh BB. Diminution of singlet oxygen-induced DNA damage by curcumin and related antioxidants. Mutat. Res. 311 (2), 249-255 (1994).
99. Dashora N, Sodde V, Bhagat J, Prabhu KS, Lobo R. Antitumor activity of dendrophthoe falcata against ehrlich as cites carcinoma in Swiss albino mice. Pharm. Crops 2, 1-7 (2011).
100. Sarhan R, El-Azim SAA, Motawi TMK, Hamdy MA. Protective effect of turmeric, Ginkgo biloba, silymarin separately or in combination, on iron-induced oxidative stress and lipid peroxidation in rats. Int. J. Pharmacol. 3 (5), 375-384 (2007).
101. Singh G, Sharma S, Choudhary N, Yadav S, Chauhan R, Dwivedi J. Evaluation of radioprotective properties of curcuma longarhizome extract: A cytogenetic analysis in cancer. Pharmacognosy Commun. 2 (2), 44-49 (2012).
102. Bhatkar SV, Rajan MG, Samuel AM. Screening for microalbuminuria by RIA in 131I-treated thyroid cancer patients. Nucl. Med. Commun. 17 (6), 536-539 (1996).
103. Bhartiya US, Joseph LJ, Raut YS, Rao BS. Effect of Ocimum sanctum, turmeric extract and vitamin E supplementation on the salivary gland and bone marrow of radioiodine exposed mice. Ind. J. Exp. Biol. 48 (6), 566-571 (2010).
104. Bhartiya US, Raut YS, Joseph LJ. Protective effect of Ocimum sanctum L after high-dose 131iodine exposure in mice: An in vivo study. Ind. J. Exp. Biol. 44 (8), 647-652 (2006).
105. Geetha RK, Vasudevan DM. Inhibition of lipid peroxidation by botanical extracts of Ocimum sanctum: In vivo and in vitro studies. Life Sci. 76 (1), 21-28 (2004).
106. Gupta S, Mediratta PK, Singh S, Sharma KK, Shukla R. Antidiabetic, antihypercholesterolaemic and antioxidant effect of Ocimum sanctum (Linn) seed oil. Ind. J. Exp. Biol. 44 (4), 300-304 (2006).
107. Kelm MA, Nair MG, Strasburg GM, Dewitt DL. Antioxidant and cyclooxygenase inhibitory phenolic compounds from Ocimum sanctum Linn. Phytomedicine 7 (1), 7-13 (2000).
108. Singh E, Sharma S, Dwivedi J, Sharma S. Diversified potentials of Ocimum sanctum Linn (Tulsi): An exhaustive survey. J. Nat. Prod. Plant Resour. 2 (1), 39-48 (2012).
109. Shetty S, Udupa S, Udupa L. Evaluation of antioxidant and wound healing effects of alcoholic and aqueous extract of Ocimum sanctum linn in rats. Evid. Based Complement. Alternat. Med. 5 (1), 95-101 (2008).
110. Talalay P, Batzinger RP, Benson AM, Bueding E, Cha YN. Biochemical studies on the mechanisms by which dietary antioxidants suppress mutagenic activity. Adv. Enzyme Regul. 17, 23-36 (1978).
111. Pattanayak P, Behera P, Das D, Panda SK. Ocimum sanctum Linn. A reservoir plant for therapeutic applications: An overview. Pharmacogn. Rev. 4 (7), 95-105 (2010).
112. Rahman S, Islam R, Kamruzzaman M, Alam K, Jamal AHM. Ocimum sanctum L: A review of phytochemical and pharmacological profile. Am. J. Drug Discov. Dev. 1-11 (2011).
113. Coyle P, Philcox JC, Carey LC, Rofe AM. Metallothionein: The multipurpose protein. Cell Mol. Life Sci. 59 (4), 627-647 (2002).
114. Dani V, Malhotra A, Dhawan D. 131I induced hematological alterations in rat blood: Protection by zinc. Biol. Trace Elem. Res. 120 (1-3), 219-226 (2007).
115. Mccall KA, Huang C, Fierke CA. Function and mechanism of zinc metalloenzymes. J. Nutr. 130 (Suppl. 5), S1437-S1446 (2000).
116. Prasad AS. Clinical, biochemical and nutritional spectrum of zinc deficiency in human subjects: An update. Nutr. Rev. 41 (7), 197-208 (1983).
117. Floersheim GL, Chiodetti N, Bieri A. Differential radioprotection of bone marrow and tumour cells by zinc aspartate. Br. J. Radiol. 61 (726), 501-508 (1988).
118. Floersheim GL, Floersheim P. Protection against ionising radiation and synergism with thiols by zinc aspartate. Br. J. Radiol. 59 (702), 597-602 (1986).
119. Matsubara J, Shida T, Ishioka K, Egawa S, Inada T, Machida K. Protective effect of zinc against lethality in irradiated mice. Environ. Res. 41 (2), 558-567 (1986).
120. Cagen SZ, Klaassen CD. Protection of carbon tetrachloride-induced hepatotoxicity by zinc: Role of metallothionein. Toxicol. Appl. Pharmacol. 51 (1), 107-116 (1979).
121. Chvapil M, Ryan JN, Zukoski CF. The effect of zinc and other metals on the stability of lysosomes. Proc. Soc. Exp. Biol. Med. 140 (2), 642-646 (1972).
122. Dani V, Dhawan DK. Radioprotective role of zinc following single dose radioiodine (131I) exposure to red blood cells of rats. Ind. J. Med. Res. 122 (4), 338-342 (2005).
123. Goel A, Chauhan DP, Dhawan DK. Protective effects of zinc in chlorpyrifos induced hepatotoxicity: A biochemical and trace elemental study. Biol. Trace Elem. Res. 74 (2), 171-183 (2000).
124. Sidhu P, Garg ML, Dhawan DK. Protective effects of zinc on oxidative stress enzymes in liver of protein deficient rats. Nutr. Hosp. 19 (6), 341-347 (2004).
125. Klaassen CD, Liu J, Choudhuri S. Metallothionein: An intracellular protein to protect against cadmium toxicity. Annu. Rev. Pharmacol. Toxicol. 39, 267-294 (1999).
126. Matsubara J, Miyata Y, Hosoi J. Alteration of radiosensitive under stressful conditions to the mouse. Radiat. Res. 24 (43-49), (1983).
127. Matsubara J, Miyata Y, Hosoi JTI. Alterations of radiosenstivity by the administration of zinc: Confounding effect of vitamin E. Radiat. Res. 25, 16-21 (1984).
128. Bucci I, Napolitano G, Giuliani C et al. Zinc sulfate supplementation improves thyroid function in hypozincemic down children. Biol. Trace Elem. Res. 67 (3), 257-268 (1999).
129. Dhawan D, Singh Baweja M, Dani V. Zinc sulphate following the administration of iodine-131 on the regulation of thyroid function, in rats. Hell. J. Nucl. Med. 10 (3), 167-171 (2007).
130. Goel A, Dhawan D, Kheruka S. Evaluation of zinc in the regulation of serum T3 and T4 levels and hepatic functions in carbontetrachloride-intoxicated rats. Biol. Trace Elem. Res. 41 (1-2), 59-68 (1994).
131. Ramirez IJ, Halwer M, Shapiro LE, Surks MI. Zinc (II) inhibits the release of thyroid and glucocorticoid receptors from chromatin of cultured GC cells. Horm. Metab. Res. 23 (4), 155-161 (1991).
132. Sustrova M, Strbak V. Thyroid function and plasma immunoglobulins in subjects with Down's syndrome (DS) during ontogenesis and zinc therapy. J. Endocrinol. Invest. 17 (6), 385-390 (1994).
133. Licastro F, Mocchegiani E, Zannotti M, Arena G, Masi M, Fabris N. Zinc affects the metabolism of thyroid hormones in children with Down's syndrome: Normalization of thyroid stimulating hormone and of reversal triiodothyronine plasmic levels by dietary zinc supplementation. Int. J. Neurosci. 65 (1-4), 259-268 (1992).
134. Anne PR, Machtay M, Rosenthal DI et al. A Phase II trial of subcutaneous amifostine and radiation therapy in patients with head-and-neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 67 (2), 445-452 (2007).
135. Wasserman TH, Brizel DM, Henke M et al. Influence of intravenous amifostine on xerostomia, tumor control, and survival after radiotherapy for head-and- neck cancer: 2-year follow-up of a prospective, randomized, Phase III trial. Int. J. Radiat. Oncol. Biol. Phys. 63 (4), 985-990 (2005).
136. Bohuslavizki KH, Klutmann S, Brenner W et al. Radioprotection of salivary glands by amifostine in high-dose radioiodine treatment. Results of a double-blinded, placebo-controlled study in patients with differentiated thyroid cancer. Strahlenther. Onkol. 175 (Suppl. 4), 6-12 (1999).
137. Bohuslavizki KH, Klutmann S, Brenner W, Mester J, Henze E, Clausen M. Salivary gland protection by amifostine in high-dose radioiodine treatment: Results of a double-blind placebo-controlled study. J. Clin. Oncol. 16 (11), 3542-3549 (1998).
138. Ma C, Xie J, Chen Q, Wang G, Zuo S. Amifostine for salivary glands in high-dose radioactive iodine treated differentiated thyroid cancer. Cochrane Database Syst. Rev. 4, CD007956 (2009).
139. Kim SJ, Choi HY, Kim IJ et al. Limited cytoprotective effects of amifostine in high-dose radioactive iodine 131-treated well-differentiated thyroid cancer patients: Analysis of quantitative salivary scan. Thyroid 18 (3), 325-331 (2008).
140. Lindegaard JC, Grau C. Has the outlook improved for amifostine as a clinical radioprotector? Radiother. Oncol. 57 (2), 113-118 (2000).
141. Rojas A, Denekamp J. The influence of x ray dose levels on normal tissue radioprotection by WR-2721. Int. J. Radiat. Oncol. Biol. Phys. 10 (12), 2351-2356 (1984).
142. Rojas A, Stewart FA, Soranson JA, Smith KA, Denekamp J. Fractionation studies with WR-2721: Normal tissues and tumour. Radiother. Oncol. 6 (1), 51-60 (1986).
143. Travis EL. The oxygen dependence of protection by aminothiols: Implications for normal tissues and solid tumors. Int. J. Radiat. Oncol. Biol. Phys. 10 (9), 1495-1501 (1984).
144. Yuhas JM, Afzal SM, Afzal V. Variation in normal tissue responsiveness to WR-2721. Int. J. Radiat. Oncol. Biol. Phys. 10 (9), 1537-1539 (1984).
145. Dreyer JO, Sakuma Y, Seifert G. Radiation-induced sialadenitis. Stage classification and immunohistology. Pathologe 10 (3), 165-170 (1989).
146. Rasey JS, Grunbaum Z, Krohn KA, Menard TW, Spence AM. Biodistribution of the radioprotective drug 35S-labeled 3-amino-2-hydroxypropyl phosphorothioate (WR77913). Radiat. Res. 102 (1), 130-137 (1985).
147. Rasey JS, Krohn KA, Grunbaum Z, Spence AM, Menard TW, Wade RA. Synthesis, biodistribution, and autoradiography of radiolabeled S-2- (3- methylaminopropylamino)ethylphosphorothioic acid (WR-3689). Radiat. Res. 106 (3), 366-379 (1986).
148. Durand RE. Radioprotection by WR-2721 in vitro at low oxygen tensions: Implications for its mechanisms of action. Br. J. Cancer 47 (3), 387-392 (1983).
149. Durand RE, Olive PL. Radiosensitisation and radioprotection by BSO and WR-2721: The role of oxygenation. Br. J. Cancer 60 (4), 517-522 (1989).
150. Savoye C, Swenberg C, Hugot S et al. Thiol WR-1065 and disulphide WR-33278, two metabolites of the drug ethyol (WR-2721), protect DNA against fast neutron-induced strand breakage. Int. J. Radiat. Biol. 71 (2), 193-202 (1997).
151. Brizel DM, Wasserman TH, Henke M et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J. Clin. Oncol. 18 (19), 3339-3345 (2000).
152. Shaw LM, Bonner H, Lieberman R. Pharmacokinetic profile of amifostine. Semin. Oncol. 23 (4 Suppl. 8), S18-S22 (1996).
153. Hosseinimehr SJ. Trends in the development of radioprotective agents. Drug Discov. Today 12 (19-20), 794-805 (2007).
154. Koukourakis MI, Danielidis V. Preventing radiation induced xerostomia. Cancer Treat. Rev. 31 (7), 546-554 (2005).
155. Stubbs M, Mcsheehy PM, Griffiths JR, Bashford CL. Causes and consequences of tumour acidity and implications for treatment. Mol. Med. Today 6 (1), 15-19 (2000).
156. Foster-Nora JA, Siden R. Amifostine for protection from antineoplastic drug toxicity. Am. J. Health Syst. Pharm. 54 (7), 787-800 (1997).
157. Utley JF, Seaver N, Newton GL, Fahey RC. Pharmacokinetics of WR-1065 in mouse tissue following treatment with WR-2721. Int. J. Radiat. Oncol. Biol. Phys. 10 (9), 1525-1528 (1984).
158. Buentzel J, Micke O, Adamietz IA, Monnier A, Glatzel M, De Vries A. Intravenous amifostine during chemoradiotherapy for head-and-neck cancer: A randomized placebo-controlled Phase III study. Int. J. Radiat. Oncol. Biol. Phys. 64 (3), 684-691 (2006).
159. Peters K, Mucke R, Hamann D, Ziegler PG, Fietkau R. Supportive use of amifostine in patients with head and neck tumors undergoing radio-chemotherapy. Is it possible to limit the duration of the application of amifostine? Strahlenther. Onkol. 175 (Suppl. 4), S23-S26 (1999).
160. Khodarev NN, Kataoka Y, Murley JS, Weichselbaum RR, Grdina DJ. Interaction of amifostine and ionizing radiation on transcriptional patterns of apoptotic genes expressed in human microvascular endothelial cells (HMEC). Int. J. Radiat. Oncol. Biol. Phys. 60 (2), 553-563 (2004).
161. Murley JS, Nantajit D, Baker KL, Kataoka Y, Li JI, Grdina DJ. Maintenance of manganese superoxide dismutase (SOD2)-mediated delayed radioprotection induced by repeated administration of the free thiol form of amifostine. Radiat. Res. 169 (5), 495-505 (2008).
162. Bohuslavizki KH, Brenner W, Klutmann S et al. Radioprotection of salivary glands by amifostine in high-dose radioiodine therapy. J. Nucl. Med. 39 (7), 1237-1242 (1998).
163. Aktoz T, Durmus-Altun G, Usta U, Torun N, Ergulen A, Atakan IH. Radioiodine-induced kidney damage and protective effect of amifostine: An experimental study. Hippokratia 16 (1), 40-45 (2012).
164. Boehme S, Wilson DB. Amifostine-induced fever: Case report and review of the literature. Pharmacotherapy 24 (1), 155-158 (2004).
165. Ma C, Xie J, Jiang Z, Wang G, Zuo S. Does amifostine have radioprotective effects on salivary glands in high-dose radioactive iodine-treated differentiated thyroid cancer. Eur. J. Nucl. Med. Mol. Imaging 37 (9), 1778-1785 (2010).
166. Rades D, Fehlauer F, Bajrovic A, Mahlmann B, Richter E, Alberti W. Serious adverse effects of amifostine during radiotherapy in head and neck cancer patients. Radiother. Oncol. 70 (3), 261-264 (2004).
167. Almeida JP, Kowalski LP. Pilocarpine used to treat xerostomia in patients submitted to radioactive iodine therapy: A pilot study. Braz. J. Otorhinolaryngol. 76 (5), 659-662 (2010).
168. Fox PC, Atkinson JC, Macynski AA et al. Pilocarpine treatment of salivary gland hypofunction and dry mouth (xerostomia). Arch. Intern. Med. 151 (6), 1149-1152 (1991).
169. Jensen SB, Pedersen AM, Vissink A et al. A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: Management strategies and economic impact. Support Care Cancer 18 (8), 1061-1079 (2010).
170. Wiseman LR, Faulds D. Oral pilocarpine: A review of its pharmacological properties and clinical potential in xerostomia. Drugs 49 (1), 143-155 (1995).
171. Gorsky M, Epstein JB, Parry J, Epstein MS, Le ND, Silverman S Jr. The efficacy of pilocarpine and bethanechol upon saliva production in cancer patients with hyposalivation following radiation therapy. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 97 (2), 190-195 (2004).
172. Haddad P, Karimi M. A randomized, double-blind, placebo-controlled trial of concomitant pilocarpine with head and neck irradiation for prevention of radiation-induced xerostomia. Radiother. Oncol. 64 (1), 29-32 (2002).
173. Hamlar DD, Schuller DE, Gahbauer RA et al. Determination of the efficacy of topical oral pilocarpine for postirradiation xerostomia in patients with head and neck carcinoma. Laryngoscope 106 (8), 972-976 (1996).
174. Horiot JC, Lipinski F, Schraub S et al. Post-radiation severe xerostomia relieved by pilocarpine: A prospective French cooperative study. Radiother. Oncol. 55 (3), 233-239 (2000).
175. Leek H, Albertsson M. Pilocarpine treatment of xerostomia in head and neck patients. Micron 33 (2), 153-155 (2002).
176. Mosqueda-Taylor A, Luna-Ortiz K, Irigoyen-Camacho ME, Diaz-Franco MA, Coll-Munoz AM. Effect of pilocarpine hydrochloride on salivary production in previously irradiated head and neck cancer patients. Med. Oral. 9 (3), 204-211 (2004).
177. Singhal S, Powles R, Treleaven J, Rattenbury H, Mehta J. Pilocarpine hydrochloride for symptomatic relief of xerostomia due to chronic graft-versus-host disease or total-body irradiation after bone-marrow transplantation for hematologic malignancies. Leuk. Lymphoma 24 (5-6), 539-543 (1997).
178. Aframian DJ, Helcer M, Livni D, Markitziu A. Pilocarpine for the treatment of salivary glands' impairment caused by radioiodine therapy for thyroid cancer. Oral Dis. 12 (3), 297-300 (2006).
179. Aframian DJ, Helcer M, Livni D, Robinson SD, Markitziu A, Nadler C. Pilocarpine treatment in a mixed cohort of xerostomic patients. Oral Dis. 13 (1), 88-92 (2007).
180. Koseki M, Maki Y, Matsukubo T, Ohashi Y, Tsubota K. Salivary flow and its relationship to oral signs and symptoms in patients with dry eyes. Oral Dis. 10 (2), 75-80 (2004).
181. Nakada K, Ishibashi T, Takei T et al. Does lemon candy decrease salivary gland damage after radioiodine therapy for thyroid cancer? J. Nucl. Med. 46 (2), 261-266 (2005).
182. Van Nostrand D, Bandaru V, Chennupati S et al. Radiopharmacokinetics of radioiodine in the parotid glands after the administration of lemon juice. Thyroid 20 (10), 1113-1119 (2010).
183. McDougall IR. Thyroid Disease in Clinical Practice. Chapman and Hall, London, UK (1992).
184. Wartofsky L, Van Nostrand D. Thyroid Cancer: A Comprehensive Guide to Clinical Management. Wartofsky L, Nostrand DV (Eds). Humana Press, NJ, USA (2006).
185. Spiegel W, Reiners C, Borner W. Sialadenitis following iodine-131 therapy for thyroid carcinoma. J. Nucl. Med. 26 (7), 816-817 (1985).
186. Ariji Y, Yuasa H, Ariji E. High-frequency color Doppler sonography of the submandibular gland: Relationship between salivary secretion and blood flow. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 86 (4), 476-481 (1998).
187. Carotti M, Salaffi F, Manganelli P, Argalia G. Ultrasonography and colour doppler sonography of salivary glands in primary Sjogren's syndrome. Clin. Rheumatol. 20 (3), 213-219 (2001).
188. Hanscheid H, Lassmann M, Luster M et al. Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: Procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. J. Nucl. Med. 47 (4), 648-654 (2006).
189. Jentzen W, Balschuweit D, Schmitz J et al. The influence of saliva flow stimulation on the absorbed radiation dose to the salivary glands during radioiodine therapy of thyroid cancer using 124I PET (/CT) imaging. Eur J. Nucl. Med. Mol. Imaging 37 (12), 2298-2306 (2010).
190. Lam MG, van Isselt JW. Does lemon candy decrease salivary gland damage after radioiodine therapy for thyroid cancer? [letter]. J. Nucl. Med. 46 (12), 2118-2121 (2005).
191. Van Nostrand D, Atkins F, Bandaru VV et al. Salivary gland protection with sialagogues: A case study. Thyroid 19 (9), 1005-1008 (2009).
192. Abramsson-Zetterberg L. Ascorbic acid is not clastogenic and does not modify the effect of extended low-dose-rate g-irradiation in mouse bone marrow. Int. J. Radiat. Biol. 70 (1), 77-81 (1996).
193. Ortmann EK, Mayerhofer T, Getoff N, Kodym R. Effect of antioxidant vitamins on radiation-induced apoptosis in cells of a human lymphoblastic cell line. Radiat. Res. 161 (1), 48-55 (2004).
194. Awad S, Henderson GB, Cerami A, Held KD. Effects of trypanothione on the biological activity of irradiated transforming DNA. Int. J. Radiat. Biol. 62 (4), 401-407 (1992).
195. Bump EA, Cerce BA, Al-Sarraf R, Pierce SM, Koch CJ. Radioprotection of DNA in isolated nuclei by naturally occurring thiols at intermediate oxygen tension. Radiat. Res. 132 (1), 94-104 (1992).
196. Chatterjee IB, Mukhopadhyay CK, Ghosh MK, Vitamin C. A potential savior against free radical-induced oxidative damage. Curr. Sci. 69 (19), 747-751 (1995).
197. Burton GW, Foster DO, Perly B, Slater TF, Smith IC, Ingold KU. Biological antioxidants. Philos. Trans. R. Soc. Lond. B Biol. Sci. 311 (1152), 565-578 (1985).
198. Allalunis-Turner MJ. Reduced bone marrow pO2 following treatment with radioprotective drugs. Radiat. Res. 122 (3), 262-267 (1990).
199. Ballardin M, Barsacchi R, Bodei L et al. Oxidative and genotoxic damage after radio-iodine therapy of Graves' hyperthyroidism. Int. J. Radiat. Biol. 80 (3), 209-216 (2004).
200. Monteiro Gil O, Oliveira NG, Rodrigues AS et al. Cytogenetic alterations and oxidative stress in thyroid cancer patients after iodine-131 therapy. Mutagenesis 15 (1), 69-75 (2000).
201. Sundaram PS, Padma S, Sudha S, Sasikala K. Transient cytotoxicity of 131I b radiation in hyperthyroid patients treated with radioactive iodine. Indian J. Med. Res. 133, 401-406 (2011).
202. Wolfram RM, Palumbo B, Chehne F, Palumbo R, Budinsky AC, Sinzinger H. (Iso) Prostaglandins in saliva indicate oxidation injury after radioiodine therapy. Rev. Esp. Med. Nucl. 23 (3), 183-188 (2004).
203. Pelton R. Ginkgo biloba. Nat. Choices 16 (16), 1-9 (1998).
204. Ringborg U, Bergqvist D, Brorsson B et al. The Swedish Council on Technology Assessment in Health Care (SBU) systematic overview of radiotherapy for cancer including a prospective survey of radiotherapy practice in Sweden 2001 - summary and conclusions. Acta Oncol. 42 (5-6), 357-365 (2003).
205. Fenech M, Morley AA. Cytokinesis-block micronucleus method in human lymphocytes: Effect of in vivo ageing and low dose x-irradiation. Mutat. Res. 161 (2), 193-198 (1986).
206. Dardano A, Ballardin M, Caraccio N et al. The effect of Ginkgo biloba extract on genotoxic damage in patients with differentiated thyroid carcinoma receiving thyroid remnant ablation with iodine-131. Thyroid 22 (3), 318-324 (2012).
207. Emerit I, Oganesian N, Sarkisian T et al. Clastogenic factors in the plasma of Chernobyl accident recovery workers: Anticlastogenic effect of Ginkgo biloba extract. Radiat. Res. 144 (2), 198-205 (1995).
208. Liu KX, Wu WK, He W, Liu CL. Ginkgo biloba extract (EGb 761) attenuates lung injury induced by intestinal ischemia/reperfusion in rats: Roles of oxidative stress and nitric oxide. World J. Gastroenterol. 13 (2), 299-305 (2007).
209. Rong Y, Geng Z, Lau BH. Ginkgo biloba attenuates oxidative stress in macrophages and endothelial cells. Free Radic. Biol. Med. 20 (1), 121-127 (1996).
210. Liu CS, Cheng Y, Hu JF, Zhang W, Chen NH, Zhang JT. Comparison of antioxidant activities between salvianolic acid B and Ginkgo biloba extract (EGb 761). Acta Pharmacol. Sin. 27 (9), 1137-1145 (2006).
211. Marcocci L, Packer L, Droy-Lefaix MT, Sekaki A, Gardes-Albert M. Antioxidant action of Ginkgo biloba extract EGb 761. Methods Enzymol. 234, 462-475 (1994).
212. Pincemail J, Dupuis M, Nasr C et al. Superoxide anion scavenging effect and superoxide dismutase activity of Ginkgo biloba extract. Experientia 45 (8), 708-712 (1989).
213. Ding XP, Qi J, Chang YX, Mu LL, Zhu DN, Yu BY. Quality control of flavonoids in Ginkgo biloba leaves by high-performance liquid chromatography with diode array detection and on-line radical scavenging activity detection. J. Chromatogr. A 1216 (11), 2204-2210 (2009).
214. Maitra I, Marcocci L, Droy-Lefaix MT, Packer L. Peroxyl radical scavenging activity of Ginkgo biloba extract EGb 761. Biochem. Pharmacol. 49 (11), 1649-1655 (1995).
215. Devi PU, Ganasoundari A. Modulation of glutathione and antioxidant enzymes by Ocimum sanctum and its role in protection against radiation injury. Indian J. Exp. Biol. 37 (3), 262-268 (1999).
216. Mediratta PK, Dewan V, Bhattacharya SK, Gupta VS, Maiti PC, Sen P. Effect of Ocimum sanctum Linn. on humoral immune responses. Indian J. Med. Res. 87, 384-386 (1988).
217. Vrinda B, Uma Devi P. Radiation protection of human lymphocyte chromosomes in vitro by orientin and vicenin. Mutat. Res. 498 (1-2), 39-46 (2001).